Nutraceuticals

<p>Section I. Applications of nutraceuticals in common diseases and disorders <br>1. Nutraceuticals in central nervous system diseases: potential mechanisms of neuroprotection <br>2. Prevention of neurodegenerative disorders by nutraceuticals <br>3. Cognitive effects of nutraceuticals <br>4. Nutraceuticals in anxiety and stress <br>5. Countering cardiovascular diseases with nutraceuticals <br>6. Nutraceuticals for diabetes and glucose balance <br>7. Role of nutraceuticals in respiratory and allied diseases <br>8. Nutraceuticals in hepatic diseases <br>9. Nutraceuticals in renal diseases <br>10. Nutraceuticals in gastrointestinal disorders <br>11. Nutraceuticals in reproductive and developmental disorders <br>12. Nutraceuticals in ophthalmic diseases <br>13. Nutraceuticals in dermal diseases<br>14. Nutraceuticals in arthritis <br>15. Nutraceuticals in sports activities and fatigue <br>16. Role of nutraceuticals as adaptogens <br>17. Nutraceuticals for weight loss <br>18. Nutraceuticals in cancer prevention<br>19. Application of “nano” nutraceuticals in medicine <br>Section II. Models and mechanisms in evaluation of nutraceuticals <br>20. The biology of nutrients: genetic and molecular principles <br>21. Genomic and proteomic mechanisms and models in toxicity and safety evaluation of nutraceuticals <br>22. Transcriptomic profiling for safety and toxicity evaluation of<br>nutraceuticals <br>23. Target identification and polypharmacology of nutraceuticals <br>24. Systems pharmacology investigation of mechanism of action of nutraceuticals<br>25. Noninvasive in vivo optical imaging models for safety and toxicity testing <br>26. Flow cytometry and light-scattering techniques in evaluation of nutraceuticals <br>27. Zebrafish as a model system to evaluate the safety and toxicity of nutraceuticals<br>28. Caenorhabditis elegans: an elegant model organism for evaluating the neuroprotective and neurotherapeutic potential of nutraceuticals <br>29. Alternative in vitro models for safety and toxicity evaluation of nutraceuticals<br>30. Mitochondria as a target for safety and toxicity evaluation of nutraceuticals<br>31. Oxidative stress and excitotoxicity: antioxidants from nutraceuticals<br>Section III. Common nutraceuticals<br>32. Caffeine: an evaluation of the safety database <br>33. Biological activities and potential nanotechnological delivery of resveratrol <br>34. Melatonin: a safe nutraceutical and clinical agent<br>35. Standardized turmeric and curcumin <br>36. Curcuminoid-metal complexes for oxidative stress<br>37. Fenugreek: multiple health benefits<br>38. Cannabis sativa: an overview<br>39. Cannabidiol safety<br>40. St John’s wort (Hypericum perforatum L)<br>41. Green tea <br>42. Green coffee beans<br>43. Quercetin<br>44. German chamomile <br>45. Isoflavones: toxicological aspects and efficacy  <br>46. Propolis <br>47. Bee products as nutraceuticals to nutraceuticals for bees <br>48. Ginkgo biloba <br>49. Chinese ginseng <br>50. Ashwagandha: multiple health benefits <br>51. Astaxanthin: health benefits and toxicity <br>52. Thymoquinone <br>53. Glucosinolates<br>54. Organosulfur compounds as nutraceuticals<br>55. Arginine and citrulline as nutraceuticals: efficacy and safety in diseases <br>56. Neem Extract<br>57. Spirulina <br>58. Garcinia cambogia <br>59. Vitamin E TPGS and its applications in nutraceuticals<br>60. Role of transferrin: an iron-binding protein in health and diseases <br>61. Glutamine supplementation: hope, hype, or stay tuned? <br>62. What to do with placenta after birth: is it a waste? <br>63. Chitin, chitosan, and their derivatives <br>Section IV. Prebiotics and probiotics <br>64. Prebiotics: safety and toxicity considerations<br>65. Probiotics: safety and toxicity considerations<br>66. Synbiotics: safety and toxicity considerations <br>Section V. Nutraceuticals in veterinary medicine <br>67. Nutraceuticals in animal health and diseases <br>Section VI. Toxicity and toxic interactions <br>68. Toxic contamination of nutraceuticals and food ingredients <br>69. Nutraceuticals and adverse outcome pathways <br>70. Interactions between nutraceuticals/nutrients and nutrients and therapeutic drugs <br>71. Genotoxicity evaluation of nutraceuticals <br>Section VII. Regulatory aspects <br>72. The regulatory framework for nutraceuticals: North America<br>73. Evaluation and regulation of food supplements: European perspective<br>74. Regulatory guidelines for nutraceuticals in India: an overview <br>75. Regulatory aspects of nutraceuticals: Chinese perspective<br>76. Uses and regulation of nutraceuticals: Australia and New Zealand <br>77. Regulatory aspects of nutraceuticals: Japanese perspective<br>78. Nutraceuticals: the Turkish perspective </p>